Association between Impella device support and elevated rates of gout flares: a retrospective propensity-matched study.
Cardiogenic shock
Circulatory failure
Gout
Hemolysis
Hemorrhage
Journal
BMC rheumatology
ISSN: 2520-1026
Titre abrégé: BMC Rheumatol
Pays: England
ID NLM: 101738571
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
received:
03
11
2023
accepted:
09
02
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
29
2
2024
Statut:
epublish
Résumé
Impella is an advanced ventricular assist device frequently used as a bridge to heart transplantation. The association of Impella with increased rates of gout flares has not been studied. Our primary aim is to determine the rates of gout flares in patients on Impella support. A retrospective study was conducted between January 2017 and September 2022 involving all patients who underwent heart transplantation. The cohort was divided into two groups based on Impella support for statistical analysis. In patients receiving Impella support, outcome measures were compared based on the development of gout flares. 1:1 nearest neighbor propensity match, as well as inverse propensity of treatment weighted analyses, were performed to explore the causal relationship between impella use and gout flare in our study population. Our analysis included 213 patients, among which 42 (19.71%) patients were supported by Impella. Impella and non-Impella groups had similar age, race, and BMI, but more males were in the Impella group. Gout and chronic kidney disease were more prevalent in Impella-supported patients, while coronary artery disease was less common. The prevalence of gout flare was significantly higher in Impella patients (30.9% vs. 5.3%). 42 Impella-supported patients were matched with 42 patients from the non-impella group upon performing a 1:1 propensity matching. Impella-supported patients were noted to have a significantly higher risk of gout flare (30.9% vs. 7.1%, SMD = 0.636), despite no significant difference in pre-existing gout history and use of anti-gout medications. Impella use was associated with a significantly increased risk of gout flare in unadjusted (OR 8.07), propensity-matched (OR 5.83), and the inverse propensity of treatment-weighted analysis (OR 4.21). Our study is the first to identify the potential association between Impella support and increased rates of gout flares in hospitalized patients. Future studies are required to confirm this association and further elucidate the biological pathways. It is imperative to consider introducing appropriate measures to prevent and promptly manage gout flares in Impella-supported patients.
Sections du résumé
BACKGROUND
BACKGROUND
Impella is an advanced ventricular assist device frequently used as a bridge to heart transplantation. The association of Impella with increased rates of gout flares has not been studied. Our primary aim is to determine the rates of gout flares in patients on Impella support.
METHODOLOGY
METHODS
A retrospective study was conducted between January 2017 and September 2022 involving all patients who underwent heart transplantation. The cohort was divided into two groups based on Impella support for statistical analysis. In patients receiving Impella support, outcome measures were compared based on the development of gout flares. 1:1 nearest neighbor propensity match, as well as inverse propensity of treatment weighted analyses, were performed to explore the causal relationship between impella use and gout flare in our study population.
RESULTS
RESULTS
Our analysis included 213 patients, among which 42 (19.71%) patients were supported by Impella. Impella and non-Impella groups had similar age, race, and BMI, but more males were in the Impella group. Gout and chronic kidney disease were more prevalent in Impella-supported patients, while coronary artery disease was less common. The prevalence of gout flare was significantly higher in Impella patients (30.9% vs. 5.3%). 42 Impella-supported patients were matched with 42 patients from the non-impella group upon performing a 1:1 propensity matching. Impella-supported patients were noted to have a significantly higher risk of gout flare (30.9% vs. 7.1%, SMD = 0.636), despite no significant difference in pre-existing gout history and use of anti-gout medications. Impella use was associated with a significantly increased risk of gout flare in unadjusted (OR 8.07), propensity-matched (OR 5.83), and the inverse propensity of treatment-weighted analysis (OR 4.21).
CONCLUSION
CONCLUSIONS
Our study is the first to identify the potential association between Impella support and increased rates of gout flares in hospitalized patients. Future studies are required to confirm this association and further elucidate the biological pathways. It is imperative to consider introducing appropriate measures to prevent and promptly manage gout flares in Impella-supported patients.
Identifiants
pubmed: 38424614
doi: 10.1186/s41927-024-00380-z
pii: 10.1186/s41927-024-00380-z
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Informations de copyright
© 2024. The Author(s).
Références
Glazier JJ, Kaki A. The Impella device: historical background, clinical applications and future directions. Int J Angiol. 2019;28(02):118–23.
doi: 10.1055/s-0038-1676369
pubmed: 31384109
Zein R, Patel C, Mercado-Alamo A, Schreiber T, Kaki A. A Review of the Impella Devices. Interventional Cardiology. 2022;17:e05 [Internet]. 2022; https://doi.org/10.15420/icr.2021.11 .
Rock JR, Kos CA, Lemaire A, Ikegami H, Russo MJ, Moin D, et al. Single center first year experience and outcomes with impella 5.5 left ventricular assist device. J Cardiothorac Surg. 2022;17(1):124.
doi: 10.1186/s13019-022-01871-1
pubmed: 35606780
pmcid: 9128113
Tonleu FHA, Zapata D, Daneshmand M, Staloch D, Agrawal A. Outcomes with Impella 5.0 and 5.5 in cardiogenic shock. J Card Fail. 2022;28(5):72.
doi: 10.1016/j.cardfail.2022.03.183
Cevasco M, Shin M, Cohen W, Helmers MR, Weingarten N, Rekhtman D et al. Impella 5.5 as a bridge to heart transplantation: Waitlist outcomes in the United States. Clin Transplant. 2023;e15066.
Vetrovec GW, Kaki A, Dahle TG, Centracare, Heart & Vascular Center, St. Cloud Hospital, St. Cloud, MN, USA. A review of bleeding risk with impella-supported high-risk percutaneous coronary intervention. Heart Int. 2020;14(2):92.
doi: 10.17925/HI.2020.14.2.92
pubmed: 36276510
pmcid: 9524743
Choi HK, Mount DB, Reginato AM. American College of Physicians, American Physiological Society. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499–516.
doi: 10.7326/0003-4819-143-7-200510040-00009
pubmed: 16204163
Textor J, Van Der Zander B, Gilthorpe MS, Liśkiewicz M, Ellison GTH. Robust causal inference using directed acyclic graphs: the R package ‘dagitty’. Int J Epidemiol. 2017;dyw341.
Ho DE, Imai K, King G, Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. J Stat Soft [Internet]. 2011 [cited 2024 Jan 14];42(8). Available from: http://www.jstatsoft.org/v42/i08/ .
Seppala LJ, Van De Loo B, Schut M, Van Schoor NM, Stricker BH, Kenny RA, et al. A propensity score matched Approach to assess the associations of commonly prescribed medications with fall risk in a large Harmonized Cohort of older ambulatory persons. Drugs Aging. 2021;38(9):797–805.
doi: 10.1007/s40266-021-00876-0
pubmed: 34224104
pmcid: 8419131
Su P, Hong L, Zhao Y, Sun H, Li L. The Association between Hyperuricemia and Hematological indicators in a Chinese Adult Population. Med (Baltim). 2016;95(7):e2822.
doi: 10.1097/MD.0000000000002822
Kumkhaek C, Shriner D, Doumatey AP, Rotimi CN, Rodgers GP. An Intergenic SNP in the β–globin gene cluster is Associated with Hyperuricemia and influences Gene transcription in Vitro. Blood. 2014;124(21):1362–2.
doi: 10.1182/blood.V124.21.1362.1362
Lauten A, Engström AE, Jung C, Empen K, Erne P, Cook S et al. Percutaneous Left-Ventricular Support With the Impella-2.5–Assist Device in Acute Cardiogenic Shock: Results of the Impella–EUROSHOCK-Registry. Circ: Heart Failure. 2013;6(1):23–30.
Badiye AP, Hernandez GA, Novoa I, Chaparro SV. Incidence of Hemolysis in patients with cardiogenic shock treated with Impella Percutaneous Left Ventricular assist device. ASAIO J. 2016;62(1):11–4.
doi: 10.1097/MAT.0000000000000290
pubmed: 26418208
Ouweneel DM, De Brabander J, Karami M, Sjauw KD, Engström AE, Vis MM, et al. Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. Eur Heart Journal: Acute Cardiovasc Care. 2019;8(4):338–49.
Bertoglio L, Katsarou M, Scandroglio M, Bertoldi L, Chiesa R, Pappalardo F. Surgical transaxillary placement of the Impella 5.0 ventricular assist device. J Card Surg. 2019;34(2):92–8.
doi: 10.1111/jocs.13978
pubmed: 30625252
Subramaniam AV, Barsness GW, Vallabhajosyula S, Vallabhajosyula S. Complications of Temporary Percutaneous Mechanical Circulatory support for cardiogenic shock: an Appraisal of Contemporary Literature. Cardiol Ther. 2019;8(2):211–28.
doi: 10.1007/s40119-019-00152-8
pubmed: 31646440
pmcid: 6828896
Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther. 1997;280(2):839–45.
pubmed: 9023298
Kahn AM. Indirect coupling between sodium and urate transport in the proximal tubule. Kidney Int. 1989;36(3):378–84.
doi: 10.1038/ki.1989.206
pubmed: 2687564
Chen KJ, Huang YC, Yao YC, Hsiung W, Chou PH, Wang ST, et al. Risk factors for postsurgical gout flares after Thoracolumbar Spine surgeries. JCM. 2022;11(13):3749.
doi: 10.3390/jcm11133749
pubmed: 35807031
pmcid: 9267449
McAdams-DeMarco MA, Maynard JW, Coresh J, Baer AN. Anemia and the onset of gout in a population-based cohort of adults: atherosclerosis risk in communities study. Arthritis Res Ther. 2012;14(4):R193.
doi: 10.1186/ar4026
pubmed: 22906142
pmcid: 3580590
Kourek C, Karatzanos E, Nanas S, Karabinis A, Dimopoulos S. Exercise training in heart transplantation. WJT. 2021;11(11):466–79.
doi: 10.5500/wjt.v11.i11.466
pubmed: 34868897
pmcid: 8603635
DeMizio D, Wu G, Wei Y, Bathon J, Wang R. Gout increases length of stay in patients hospitalized for heart failure exacerbation. Therapeutic Adv Musculoskelet. 2022;14:1759720X2211028.
doi: 10.1177/1759720X221102853
Zleik N, Elfishawi MM, Kvrgic Z, Michet CJ, Crowson CS, Matteson EL, et al. Hospitalization increases the risk of Acute arthritic flares in gout: a Population-based study over 2 decades. J Rheumatol. 2018;45(8):1188–91.
doi: 10.3899/jrheum.171320
pubmed: 29961683
pmcid: 6072557
Ritter F, Franzeck F, Geisshardt J, Walker UA, Osthoff M. Gout arthritis during admission for decompensated heart Failure—A descriptive analysis of risk factors, treatment and prognosis. Front Med. 2022;9:789414.
doi: 10.3389/fmed.2022.789414
Benavent D, Peiteado D, Martinez-Huedo MÁ, Hernandez-Hurtado M, Balsa A, De Miguel E. Healthcare-related impact of gout in hospitalized patients in Spain. Sci Rep. 2021;11(1):13287.
doi: 10.1038/s41598-021-92673-3
pubmed: 34168227
pmcid: 8225766